The active substance in Диотензин is losartan, which is an Angiotensin II Receptor Blocker (ARB). Losartan is commonly used to help with several conditions associated with acute or disruptive episodes of cardiovascular and renal stress.

---

What Диотензин treats: main uses and benefits

The main therapeutic uses of the active substance in Диотензин are applied in addressing conditions marked by increased physiological stress, such as hypertension (high blood pressure), and to assist with aspects of organ-specific functional stability in certain patients. The medicine is commonly used to help with several key conditions.

The medicine supports general well-being during symptomatic phases and is relevant for easing symptoms related to inflammatory or irritative states often seen in essential hypertension, renal disease in patients with hypertension and Type 2 Diabetes Mellitus, left-ventricular hypertrophy in hypertensive patients, and chronic heart failure. The drug is applied in scenarios where additional management of discomfort is required and contributes to improved comfort during periods of heightened symptoms. This is relevant in clinical settings that involve acute or unstable symptom patterns.

---

Quick Fact: Relief for Symptoms related to systemic imbalance

---

Eligibility Map: Who Can and Cannot Use Диотензин — Official Regulatory Information

Contraindicated Populations (Must Not Use)

The active substance, losartan, is contraindicated in pregnancy; it must be discontinued immediately upon detection due to the risk of fetal toxicity. Use is also prohibited in patients with a known hypersensitivity to losartan or any component. A further absolute exclusion applies to patients with diabetes who are simultaneously taking aliskiren, and those with severe hepatic impairment (severely reduced liver function).

Age-Related and Conditional Eligibility

The medicine is approved for adults and children aged 6 years and older for the treatment of high blood pressure. Use is not recommended in pediatric patients younger than 6 years of age or those with a Glomerular Filtration Rate (GFR) less than 30 mL/ min/1.73 m^2. Losartan is not recommended for use by breastfeeding mothers. Furthermore, patients with mild-to-moderate hepatic impairment or those who are volume-depleted are only eligible under restricted conditions.

The official regulatory profile for Диотензин (losartan) details several documented interaction patterns based on pharmacodynamic risk and metabolic modification of drug exposure. The primary concern is the additive risk of hyperkalemia (high potassium levels) and effects on renal function.

Interaction Classifications and Restrictions

Category	Description based on Official Documents
Contraindicated Combination	Co-administration with Aliskiren is strictly prohibited in patients with diabetes mellitus or specific forms of renal impairment (GFR < 60 mL/min/1.73 m²).
Not Recommended	Concomitant use with Potassium-sparing diuretics (e.g., Spironolactone), Potassium supplements, and Potassium-containing salt substitutes is not recommended due to the high risk of hyperkalemia.

Documented Interaction Statements

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), including selective COX-2 inhibitors, are associated with an increased risk of renal function deterioration and may diminish the antihypertensive effect.
• The co-administration of Lithium results in a pharmacodynamic interaction leading to increased plasma levels of lithium, carrying a risk of toxicity due to reduced renal clearance.
• Metabolic interactions involving the CYP2C9 enzyme have been documented: Fluconazole increases the systemic exposure (AUC) of losartan while reducing the exposure of its active metabolite, and Phenobarbital reduces the exposure of both losartan and its active metabolite.
• Alcohol (Ethanol) and other antihypertensive agents may result in additive effects, increasing the risk of hypotension (low blood pressure).

Population-specific interaction notes indicate that Severe Hepatic Impairment increases the concentration of losartan in the plasma, signifying a heightened interaction severity risk in this population.

Angiotensin Receptor Blockade

This mechanistic domain involves the selective, competitive binding of Losartan to the Angiotensin II type 1 (AT1) receptors located in smooth muscle tissue and the adrenal glands. This interaction prevents the binding of endogenous Angiotensin II, thereby interrupting its signaling cascade. The intracellular consequence is the mitigation of vasoconstriction and a decrease in aldosterone secretion. At the system level, this leads to the relaxation of blood vessels (vasodilation) and a reduction in systemic vascular resistance.

Renal Electrolyte Transport Modulation

This second domain involves Hydrochlorothiazide, which acts by engaging mechanisms that inhibit the sodium-chloride cotransporter (NCC) in the luminal membrane of the distal convoluted tubule within the kidney. Inhibition of this transporter suppresses the reabsorption of sodium and chloride ions from the renal filtrate. This modification results in a sustained increase in the excretion of sodium and water, leading to a consequent decrease in extracellular fluid volume and plasma volume.

The simultaneous engagement of these two distinct domains facilitates the concurrent adjustment of both the renin-angiotensin-aldosterone system (RAAS) and volume homeostasis.

How to Use Диотензин: Official Administration Guidelines

Диотензин, containing the active substance Losartan, is administered via the oral route as a film-coated tablet or, if compounded, as a liquid suspension. The medicine is typically taken once daily and may be administered with or without food. Standard practice requires the tablets to be swallowed whole with water, though the 50 mg tablet is officially scored and may be divided into two equal doses.

---

Standard Labeled Dosing Regimens

Indication	Starting Dose	Maximum Daily Dose	Frequency
Hypertension	50 mg	100 mg	Once Daily
Type 2 Diabetic Nephropathy	50 mg	100 mg	Once Daily
Chronic Heart Failure	12.5 mg	150 mg	Once Daily

---

Dosing Adjustment and Administration Context

The dosage is not immediately adjusted; the full therapeutic effect is typically assessed after 3 to 6 weeks of consistent use. For patients with mild-to-moderate hepatic impairment or those who are volume-depleted, an initial dose reduction to 25 mg once daily is specified to ensure proper systemic exposure. In the treatment of chronic heart failure, the initial 12.5 mg dose is gradually increased through titration, typically at weekly intervals, as described in the official protocol. Pediatric patients aged 6 to 18 years with hypertension use a weight-based regimen, starting at 0.7 mg/kg once daily.

Recent Clinical Evidence Overview

Overview of Clinical Trial Focus

Early research focused on how the drug affects the body, suggesting it targets the central nervous system. Research evaluated the drug's effect on pain and inflammation metrics associated with conditions like osteoarthritis (OA). The body of evidence consists primarily of Randomized Controlled Trials (RCTs) and several cohort studies.

• Phase II Trials: Initial trials focused on evaluating different dosage levels and established preliminary safety profiles.
• Phase III Trials: Larger trials evaluated the drug's short-term effects compared to a placebo across various pain conditions.

---

Detailed Findings by Condition

Acute Pain

Clinical trials investigated whether a higher dosage was associated with differences in the timing of pain-related symptom changes for acute pain episodes. The results of these investigations were varied, with some studies reporting no significant difference between the high and standard doses.

Chronic Inflammatory Conditions

A significant portion of the evidence focused on participants with chronic inflammatory pain. Clinical investigations reported changes in chronic pain scores, with follow-up data extending to 12 months. Studies assessed whether the use of the drug was associated with improvements in the WOMAC Index (a metric of pain, stiffness, and function) over six months. Findings were mixed regarding sustained functional improvement beyond this period.

Condition Studied	Primary Research Metric	Key Finding (Neutral Summary)
Osteoarthritis (OA)	WOMAC Index	Improvement in pain and function metrics over 6 months; long-term data showed mixed results
Rheumatoid Arthritis (RA)	Tolerability/Adjunctive Use	Research explored the drug’s tolerability and effect as an adjunctive therapy

---

Safety and Tolerability Research

Research examined whether taking the drug with food, as specified in some trial protocols, impacted reported gastrointestinal events. Studies also examined whether the use of the lowest possible dose was associated with differences in outcomes. Its properties have been the subject of research; studies have examined whether its use is associated with changes in markers of joint damage over time. Specific evidence is not widely available regarding long-term outcomes in populations aged over 75.

Key Studies & References

1. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Common questions about Диотензин (FAQ)

---

Q: How quickly can a person expect Диотензин to start affecting their blood pressure readings?

Official prescribing information indicates that the full therapeutic effects of the medicine are typically assessed by a healthcare provider after 3 to 6 weeks of consistent daily use. The full effect of blood pressure lowering may take several weeks to be established, as indicated in the prescribing information.

Q: What symptoms should prompt a person to contact a healthcare professional immediately regarding Диотензин?

Official documentation notes that clinically significant adverse events, such as swelling of the face, tongue, or throat (angioedema) or signs of acute renal failure, are explicitly noted as situations that require prompt medical evaluation. These are considered serious adverse events documented in the prescribing information.

Q: Can a person take over-the-counter pain relievers or cold medicines while using Диотензин?

Official interaction statements highlight that using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) while taking this medicine may be associated with an increased risk of kidney function deterioration. Additionally, NSAIDs may reduce the intended blood pressure-lowering effect. Regulatory patient information emphasizes the importance of discussing all medicines and supplements with a healthcare provider.

Q: Why would a doctor choose to prescribe Диотензин over a different class of medicine?

The official indications for this medicine include its use for managing hypertension, treating Type 2 diabetic nephropathy (kidney disease in diabetes), and for treating chronic heart failure. Official labels also note its use in reducing stroke risk in certain patients with high blood pressure. The determination of whether these approved uses make it suitable for an individual is managed by a healthcare professional.

Q: What is angioedema and is there a risk of it when taking Диотензин?

Angioedema is a documented, rare but serious adverse reaction that involves the swelling of the face, lips, tongue, or throat. This reaction is explicitly noted in official labeling for this medicine. Symptoms of swelling are explicitly noted in official labeling as events that require prompt medical evaluation.

Q: Can people with diabetes or high cholesterol take Диотензин?

Official documents include the treatment of Type 2 diabetic nephropathy as an approved use for this medicine. However, official regulatory information strictly prohibits the co-administration of this medicine with Aliskiren in patients who have diabetes. The regulatory warnings do not address high cholesterol as a condition affecting eligibility.

Q: If blood pressure readings become normal, is it safe to stop taking Диотензин without consulting a doctor?

The medicine is officially intended for long-term therapeutic management of blood pressure. Abruptly stopping any medication used to treat hypertension carries a documented risk of a blood pressure rebound. The official documentation describes this medicine as a long-term maintenance therapy, and all decisions regarding changes to treatment are managed by a healthcare professional.

Q: Does taking Диотензин mean my high blood pressure is permanently cured?

Official regulatory documents indicate the medicine is intended for the long-term therapeutic management of chronic high blood pressure. The term 'cure' is not used in official documentation to describe the outcome of treatment for this chronic condition.

Q: What happens if a person occasionally misses a dose of Диотензин?

The regulatory patient information advises that if a person remembers a missed dose, they should take it right away. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. Official regulatory patient information notes that a double dose must not be taken to compensate for a missed dose.

Q: Is a persistent, dry cough a known side effect of Диотензин?

Cough is a documented adverse event associated with this medicine. However, official studies have described its occurrence as being significantly lower than with other classes of blood pressure medication, such as ACE inhibitors.

Q: How is Диотензин different from other types of blood pressure medications?

The official mechanism describes that this medicine works by selectively blocking the Angiotensin II type 1 (AT1) receptor. This means the medicine prevents the hormone Angiotensin II from acting on specific receptors in the body. This mode of action is distinct from other classes of blood pressure medications, such as ACE inhibitors.

Q: Is there a generic version of Диотензин available?

The active ingredient in this medicine is Losartan, which is recognized by its International Nonproprietary Name (INN). Losartan is available as a lower-cost generic product.

Q: Is it possible for Диотензин to be prescribed as a combination pill with another drug?

Losartan, the active substance, is available in a fixed-dose combination with other medications, such as hydrochlorothiazide (a diuretic), in a single tablet form. This combination is an approved treatment option for hypertension.

Q: Are there any studies on the long-term safety profile of Диотензин?

Regulatory documents require mandatory, long-term monitoring of serum electrolytes (such as potassium) and renal function for individuals taking this medicine. These monitoring requirements are specified to manage documented risks of electrolyte imbalance and potential changes to kidney function associated with sustained use.

Q: Can Диотензин cause fatigue or unusual tiredness?

Fatigue or unusual tiredness is a documented adverse effect of the active substance in this medicine. It is classified in official documents as a common adverse reaction.

Q: Does Диотензин interact with common supplements like vitamin D or fish oil?

Official regulatory documentation does not list specific interactions for common supplements like Vitamin D or fish oil. However, regulatory patient information generally advises patients to inform their healthcare professional about all prescription, non-prescription, and herbal supplements they take.

Q: Is Диотензин recommended for people over the age of 65?

Official guidelines indicate that no routine dosage adjustment is typically required solely based on age for elderly patients. However, the prescribing information does contain specific dosing and safety considerations for patients over 75 years of age.

Q: Is it common for Диотензин to be used in combination with a diuretic ('water pill')?

Losartan is commercially available in a fixed-dose combination with a diuretic, often referred to as a 'water pill.' This combination is a common treatment strategy used to achieve further reduction in high blood pressure.

Q: How can I monitor if Диотензин is working effectively for me?

The effectiveness of the medicine is officially assessed by tracking regular blood pressure measurements. This assessment is usually determined after 3 to 6 weeks of consistent use. Mandatory monitoring of serum electrolytes and renal function is also required during treatment.

Q: Is it possible to develop a rash while taking Диотензин?

Rash is a documented, less common adverse reaction to this medicine. This symptom, along with itching or hives, is also listed as a potential sign of an allergic reaction.

Q: What is the difference between the active ingredient and the inactive ingredients in Диотензин?

The active ingredient is Losartan potassium, which is the compound that produces the intended blood pressure-lowering effect. Inactive ingredients are the other components of the tablet, such as colorants, fillers, and binders, which do not have a pharmacological effect.

Q: Is there evidence regarding how Диотензин performs in different patient populations or ethnic groups?

Official prescribing information contains specific population notes regarding the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy. The documentation indicates that the benefit for this specific use does not apply to Black patients.

Q: What is the purpose of the warning statements provided in the official documentation for Диотензин?

Warning statements and mandatory monitoring requirements are included in the official documentation to inform patients about the documented risks associated with the medicine. The information provided is intended to make users aware of potential issues, such as documented risks to kidney function or serum electrolyte levels.

How to Store and Dispose of Диотензин?

Storing Диотензин correctly is essential to maintain its stability and effectiveness, as defined by official regulatory requirements.

Storage Requirement	Official Guideline
Temperature	Store at a temperature not exceeding 25 C.
Handling & Protection	Protect the medicine from freezing. Keep containers closed in the original package to shield it from light and moisture.
Security	Keep this medicine strictly out of the sight and reach of children and domestic pets.

For disposal, do not throw away unused or expired Диотензин in household trash or pour it into a drain or toilet. Proper disposal minimizes environmental impact and accidental exposure. The official guideline is to dispose of medicine according to local regulations, which often means utilizing an authorized drug take-back program. Consult a pharmacist or local waste disposal service for the proper procedure in your area.